Jefferies analyst Matthew Andrews downgraded Gemphire Therapeutics (NASDAQ: GEMP) to Hold today and set a price target of $2. The company’s shares closed on Friday at $1.80, close to its 52-week low of $0.83.
According to TipRanks.com, Andrews is a 5-star analyst with an average return of 30.0% and a 45.7% success rate. Andrews covers the Healthcare sector, focusing on stocks such as Urogen Pharma Ltd, CTI BioPharma, and Sesen Bio Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gemphire Therapeutics with a $11.67 average price target, a 548.3% upside from current levels. In a report issued on August 7, Raymond James also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.43 and a one-year low of $0.83. Currently, Gemphire Therapeutics has an average volume of 723.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.
Read More on GEMP:
